Randomized trial demonstrates improved wakefulness and reduced cataplexy with oveporexton in narcolepsy type 1, suggesting targeted orexin receptor activation effectively manages core symptoms.
In this phase 2 trial involving participants with narcolepsy type 1, oveporexton significantly improved measures of wakefulness, sleepiness, and cataplexy over a period of 8 weeks. (Funded by Takeda Development Center Americas; TAK-861-2001 ClinicalTrials.gov number, NCT05687903.).
No takes yet. Share an insight, caveat, or question.
Dauvilliers et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: